Abstract: The present disclosure provides recombinant host cells comprising a pathway capable of producing a cannabinoid and a heterologous nucleic acid that encodes a protein not in the pathway that enhances the host cells’ ability to produce the cannabinoid. The disclosure also provides methods of using host cells to produce cannabinoids.

Abstract: The present invention provides methods for treatment of a RAS-positive disease, in particular KRAS-positive non-small cell lung cancer as well as a method for potentiating the apoptotic activity of a PDE? inhibitor by combining the PDE? inhibitor with a direct autophagy inhibitor. The PDE? inhibitor is preferably, but not exclusively, deltarasin, and the direct autophagy inhibitor is in particular 3-methyladenine. Further provided by the present invention are a kit and a pharmaceutical composition comprising the PDE? inhibitor and a direct autophagy inhibitor. The methods of the present invention in particular provide a new treatment option for RAS-positive diseases such as KRAS-positive non-small cell lung cancer allowing for an increased apoptotic activity of the PDE? inhibitor by simultaneously blocking its “tumor protective” autophagy.

Abstract: One example embodiment relates to a method of treating lung cancer by administering a compound of formula I to a subject in need thereof. Another embodiment relates to a method to treat Non-Small Cell Lung Cancer (NSCLC) by administering the compound of formula I to a patient.